胃旁路术优于袖状胃切除术（反流更少），并且可以彻底治疗 2型糖尿病；对于节食失败的患者，应选择胃旁路术而不是袖状胃切除术（2021 年的言论）。
原始表述
ويجي يقولي أنا عايز أعمل عملية تحويل المسار بدون نقاش التكميم عملية سيئة ومشاكلها كثيرة
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
胃旁路术优于袖状胃切除术（反流更少），并且可以彻底治疗 2型糖尿病；对于节食失败的患者，应选择胃旁路术而不是袖状胃切除术（2021 年的言论）。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- عمليات السمنة ايه افضل عملية لصحتك وبدون خطورة (打开来源)
- 发布日期
- 2021年3月31日
- 时间戳
- 0:02:26 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); wording may contain transcription errors; no timestamps available. Embedded time marker approx. [02:25] in archive transcript.
- 所声称的机制
Bypass diverts carbohydrate load away from pancreas/liver.
- 所声称的健康影响
Diabetes cure; less reflux.
- 涉及人群
Patients who failed diet
- Elawady 设定的地域限制
none found
科学评估
基本正确 – 核心内容正确，但有局限或细微不准确之处。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
Bypass better than sleeve; bypass can fully cure T2D.
2. 哪些内容可证实是正确的？
Reflux: bypass superior (SLEEVEPASS esophagitis 7% vs 31%; SM-BOSS reflux remission 60.4% vs 25.0%; STAMPEDE, A-BAR-24: GERD reported in 10% after bypass vs 27% after sleeve at 5 years). Weight loss modestly greater after bypass (SLEEVEPASS +8.4 %EWL).
3. 哪些内容是错误或夸大的？
'Can treat diabetes completely' is overstated: diabetes remission after bypass declines (Adams 51% at 12 years; Mingrone RYGB 25% at 10 years) and SLEEVEPASS/STAMPEDE show no significant remission difference between bypass and sleeve. In STAMPEDE only 22.4% of bypass patients reached HbA1c <=6.0% without diabetes medication at 5 years (A-BAR-24; trial not powered for bypass vs sleeve). Bypass carries specific harms (A-BAR-10, A-BAR-11, A-BAR-14, I-BAR-08).
4. 哪些内容仍不明确？
Individual choice depends on reflux, BMI, diabetes and patient factors.
5. 哪些研究支持该说法？
A-BAR-07, I-BAR-05; Oseberg RCT 5-year remission 50% vs 20% and less pathological reflux after bypass (I-BAR-116); SM-BOSS >=10 years: conversions 5.5% vs 29.9% and less de novo GERD after bypass (I-BAR-142); lower relapse after bypass (I-BAR-131, I-BAR-134); consensus favouring bypass in significant GERD (I-BAR-113).
6. 哪些研究与该说法相矛盾？
A-BAR-04, I-BAR-03, A-BAR-24, A-BAR-14, I-BAR-08; even after bypass, about one third of remitters relapse within 5 years (I-BAR-134) and only half were in remission at 5 years in Oseberg (I-BAR-116); bypass has more bone loss and fractures (I-BAR-123, I-BAR-126), more B12 deficiency (I-BAR-121), more postprandial hypoglycaemia (I-BAR-116), and an observational meta-analysis found higher medium-term mortality than after sleeve (sleeve HR 0.85, I-BAR-135).
7. 对德国和欧洲而言情况如何？
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
8. 关于埃及的已知情况是什么？
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
9. 合理的实际结论是什么？
术式的选择应因人而异；存在反流时，通常首选胃旁路术。
评估详情
- 证据确定性的依据
Two RCTs show less reflux after bypass; diabetes 'complete cure' is overstated.
- 来源质量
Short 2021 video; position differs from his later statements opposing all bariatric operations (2025: 'against any operation', 'sleeve is a crime'). Both positions are recorded; no motive is implied.
- 地区可推广性
European RCTs.
- 个体例外情况
Bypass has its own risks (alcohol use disorder, bone loss, internal hernia, marginal ulcer).
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
仅在特定条件下成立 – 该说法仅在特定剂量、特定人群、特定制备方式或特定情况下成立。
研究问题: Is gastric bypass preferable to sleeve gastrectomy (less reflux, better diabetes outcomes), and can bypass fully cure type 2 diabetes?
研究问题详解 (PICO)
- 人群
- Adults with severe obesity (with or without T2D/GERD) choosing a bariatric procedure
- 干预或暴露
- Roux-en-Y gastric bypass
- 对照
- Sleeve gastrectomy
- 地域范围
- universal biology
- 结局指标
- GERD
- T2D remission and relapse
- Mortality
- Reoperations
- Bone, nutritional and alcohol harms
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Norwegian trial: bypass vs sleeve in type 2 diabetes
Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6 随机对照试验已核查摘要新增Oseberg RCT: bypass doubled 5-year diabetes remission vs sleeve and caused less acid reflux.
- 实际结果
- Remission 50% vs 20%; pathological reflux RD 51%.
- 方法学质量
- high (small RCT)
- 相关性
- direct
- 局限
- n=109
Swiss trial: sleeve vs bypass after 10 years
SM-BOSS: fewer conversions and less de novo GERD after bypass at >=10 years.
- 实际结果
- Conversions 5.5% vs 29.9%.
- 方法学质量
- high
- 相关性
- direct
- 局限
- Attrition
Finnish trial: sleeve vs bypass after 10 years
SLEEVEPASS: oesophagitis 7% vs 31%.
- 实际结果
- 7% vs 31%.
- 方法学质量
- high
- 相关性
- direct
哪些证据不支持该说法？
Meta-analysis: survival after sleeve vs bypass
Sakurai et al.. Surg Obes Relat Dis 2025 · PMID 39732586 · DOI 10.1016/j.soard.2024.11.016 Meta分析已核查摘要新增Meta-analysis: lower all-cause mortality, reoperation and hospitalisation after sleeve than bypass.
- 实际结果
- Mortality HR 0.85 (0.79-0.92) SG vs RYGB.
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Observational, short
French study: broken bones after obesity surgery
French cohort: fractures increased after bypass, not sleeve.
- 实际结果
- Bypass HR 1.70.
- 方法学质量
- moderate
- 相关性
- direct (harm trade-off)
US study: diabetes 5 years after bypass vs sleeve
PCORnet: even after bypass, a third of remitters relapsed within 5 years.
- 实际结果
- Relapse 33.1% (RYGB).
- 方法学质量
- moderate
- 相关性
- direct to "full cure"
- 局限
- Observational
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Bypass is better than sleeve for reflux and somewhat better for diabetes remission and durability, so it is commonly preferred when reflux or diabetes is prominent; but it has its own harms (more bone loss, B12 deficiency, alcohol problems, hypoglycaemia, possibly higher medium-term mortality), does not reliably cure diabetes, and procedure choice should be individual.
为什么有些研究权重更大
Three RCTs (SLEEVEPASS, SM-BOSS, Oseberg) for reflux/diabetes; observational data for harms and mortality.
因果关系是否已确立？ 是，已确立 RCT comparisons for reflux and remission.
仍存在的不确定性
Long-term mortality difference between procedures.
合理的结论
Comparative statements mostly correct; "full cure" and a universal preference overstated.
为什么研究结果看起来互相矛盾？
Bypass better for reflux/diabetes (RCTs) vs sleeve lower medium-term mortality and fewer reoperations (observational meta-analysis): these are different outcomes and represent a trade-off, not a contradiction.
这是否取决于国家？
- 一般生物学效应
- Universal.
- 饮食习惯
- Not applicable (surgical procedure, not a food).
- 食品原产地
- Not applicable (surgical procedure, not a food).
- 污染物
- Not applicable (surgical procedure, not a food).
- 本国生产条件
- Not applicable.
- 法律规则
- Not applicable.
- 实际监测数据
- No Egyptian comparative data found.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Reproduce risk differences – Remission RDs 29.5% and 33.5% reproduced; hypoglycaemia RD 26% (assuming randomised denominators). 已重新计算
- CI symmetry of relapse HR – HR 0.75 (0.67-0.84) symmetric. 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Reflux and T2D remission, bypass vs sleeve
- 起始等级
- 高（随机试验）
- 降级理由
- imprecision (small RCTs)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- International expert consensus (Montpellier): GERD and LSG: First International Consensus Conference (I-BAR-113) (2020) · 原始文献
GERD is probably the main drawback of LSG; endoscopy before (92%) and after (78%) surgery; higher-grade oesophagitis and Barrett are contraindications to LSG; RYGB recommended for uncontrolled GERD after sleeve. - ADA: Standards of Care in Diabetes-2026, Section 8 (I-DIAB-113) (2026) · 原始文献
Consider metabolic surgery in type 2 diabetes with BMI >=30 (>=27.5 Asian American) (A); long-term medical and behavioural support with routine micronutrient and metabolic monitoring (B); routine psychosocial screening after surgery (C); text cites lower relapse after RYGB than sleeve (5-y relapse 33.1% vs 41.6%).
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | McTigue KM[au] AND sleeve gastrectomy AND gastric bypass AND diabetes AND JAMA Surg[ta] | 双向 | 2 | |
| PubMed | 2026年10月26日 | (Oseberg OR Hofso D[au]) AND gastric bypass AND sleeve gastrectomy AND diabetes remission AND randomised | 双向 | 12 | |
| PubMed | 2026年10月26日 | (sleeve gastrectomy[ti]) AND (gastroesophageal reflux[tiab] OR GERD[tiab]) AND (de novo[tiab]) AND (systematic review[pt] OR meta-analysis[pt] OR randomized controlled trial[pt]) | 支持性证据 | 22 | |
| Europe PMC | 2026年10月26日 | (TITLE:"bariatric" OR TITLE:"sleeve gastrectomy" OR TITLE:"metabolic surgery") AND (TITLE:"mortality" OR TITLE:"survival" OR TITLE:"life expectancy") AND (PUB_TYPE:"Meta-Analysis" OR TITLE:"meta-analysis") AND PUB_YEAR:[2019 TO 2026] | 反对性证据 | 14 |
待解决的问题
Long-term mortality comparison in RCTs.
核查深度如何？
18 项相关研究：3 项核查了全文（其中 3 项进行了结构化偏倚风险评估），15 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本正确 (中)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 基本正确 (中)
Unchanged (MOSTLY_TRUE, moderate). New RCT data (Oseberg 5 y, SM-BOSS 10 y) strengthen the comparative part; new harm/mortality data strengthen the caveats.
新来源: I-BAR-113 I-BAR-116 I-BAR-131 I-BAR-134 I-BAR-142 I-BAR-121 I-BAR-123 I-BAR-126 I-BAR-135
通俗解释
在 2021 年的一个视频中，Elawady 说，袖状胃切除术因为反流是一种糟糕的手术，无法通过饮食减重的患者应选择胃旁路术，它可以"彻底"治疗糖尿病。关于反流的部分与随机对照试验相符。彻底治愈糖尿病的想法则过于乐观，因为在许多患者中，糖尿病会在多年后复发。在后来的视频中（2025 年），他反对所有此类手术。
与该说法相关的研究
支持该说法的研究 (7)
-
Finnish trial: sleeve vs bypass after 10 years
Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究Esophagitis was found in 31% after sleeve vs 7% after bypass; Barrett's esophagus was 4% in both groups.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare sleeve vs bypass
- 研究是如何开展的？
RCT with 10-year follow-up
- 研究了多少人、动物或样本？
240 patients
- 实际发现了什么？
More esophagitis after sleeve; Barrett's equal
- 观察到的效应有多大？
31% vs 7%; BE 4% vs 4%
- 研究结果对日常生活意味着什么？
Sleeve often causes reflux damage; bypass less so
- 该研究有哪些局限？
Attrition; small
- 它对 Elawady 的具体说法说明了什么？
Supports reflux claim, not sleeve-specific Barrett's
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Cancer risk
-
Swiss trial: sleeve vs bypass
Peterli R et al.. JAMA 2018 · PMID 29340679 · DOI 10.1001/jama.2017.20897随机对照试验独立交叉核查已核查摘要★ 关键研究Reflux got worse in about 32% after sleeve vs 6% after bypass.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare procedures
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
217
- 实际发现了什么？
More reflux after sleeve
- 观察到的效应有多大？
31.8% vs 6.3%
- 研究结果对日常生活意味着什么？
Reflux is common but not universal
- 该研究有哪些局限？
Exploratory reflux outcome
- 它对 Elawady 的具体说法说明了什么？
Supports increase, refutes 'inevitable'
- 研究结果是否适用于德国和欧洲？
European
- 从该研究中明确不能得出什么结论？
Long-term BE
-
International experts on reflux and sleeve
Assalia et al.. Obes Surg 2020 · PMID 32533520 · DOI 10.1007/s11695-020-04749-0指南 / 立场声明独立交叉核查已核查摘要Experts agreed that reflux is probably the main drawback of sleeve and that bypass is preferable when severe reflux exists.
Bypass preferred for significant GERD/Barrett.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Agree on GERD management
- 研究是如何开展的？
Expert consensus
- 研究了多少人、动物或样本？
46 experts
- 实际发现了什么？
Endoscopy before/after; bypass for severe GERD
- 观察到的效应有多大？
Agreement %
- 研究结果对日常生活意味着什么？
Doctors take reflux after sleeve seriously
- 该研究有哪些局限？
Opinion-based
- 它对 Elawady 的具体说法说明了什么？
Supports reflux concern
- 研究结果是否适用于德国和欧洲？
International
- 从该研究中明确不能得出什么结论？
Does not condemn sleeve generally
-
Norwegian trial: bypass vs sleeve in type 2 diabetes
Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6随机对照试验独立交叉核查已核查摘要★ 关键研究After 5 years, diabetes was in remission in 50% after bypass vs 20% after sleeve; acid reflux was more common after sleeve, but Barrett changes were similar.
Bypass superior for T2D remission (50% vs 20%) and pathological reflux; but only half in remission and more hypoglycaemia.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare RYGB and SG in T2D
- 研究是如何开展的？
Randomised trial
- 研究了多少人、动物或样本？
109
- 实际发现了什么？
Bypass better for remission and weight; sleeve more acid reflux
- 观察到的效应有多大？
RD 29.5%
- 研究结果对日常生活意味着什么？
Bypass helps diabetes more but is not a cure
- 该研究有哪些局限？
Small, single centre
- 它对 Elawady 的具体说法说明了什么？
Supports bypass preference for diabetes/reflux; contradicts "complete cure"
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Long-term hard outcomes
-
Meta-analysis: diabetes returning after bypass
Yu et al.. Obes Surg 2021 · PMID 34505971 · DOI 10.1007/s11695-021-05692-4Meta分析独立交叉核查已核查摘要About 3 in 10 people whose diabetes went into remission after bypass later relapsed; relapse was less common than after sleeve.
Lower relapse after RYGB than SG (HR 0.73).
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Relapse after RYGB
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
17 studies
- 实际发现了什么？
Relapse 30%
- 观察到的效应有多大？
HR 0.73 vs SG
- 研究结果对日常生活意味着什么？
Remission is not always permanent
- 该研究有哪些局限？
Observational
- 它对 Elawady 的具体说法说明了什么？
Supports erosion claim
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Effect on complications
-
US study: diabetes 5 years after bypass vs sleeve
McTigue et al.. JAMA Surg 2020 · PMID 32129809 · DOI 10.1001/jamasurg.2020.0087队列研究独立交叉核查已核查摘要★ 关键研究Diabetes remission was slightly more common and relapse less common after bypass; still, about 1 in 3 remitted bypass patients relapsed within 5 years.
RYGB slightly better remission and less relapse than SG; but relapse common after RYGB too.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare T2D outcomes RYGB vs SG
- 研究是如何开展的？
Cohort
- 研究了多少人、动物或样本？
9,710
- 实际发现了什么？
Relapse 33% vs 42%
- 观察到的效应有多大？
Relapse HR 0.75
- 研究结果对日常生活意味着什么？
Bypass a bit better; neither is a guaranteed cure
- 该研究有哪些局限？
Observational
- 它对 Elawady 的具体说法说明了什么？
Supports relapse claim; contradicts "complete cure"
- 研究结果是否适用于德国和欧洲？
Plausible
- 从该研究中明确不能得出什么结论？
Hard outcomes
-
Swiss trial: sleeve vs bypass after 10 years
Kraljevic et al.. JAMA Surg 2025 · PMID 39969869 · DOI 10.1001/jamasurg.2024.7052随机对照试验独立交叉核查已核查摘要★ 关键研究After more than 10 years, 3 in 10 sleeve patients needed a conversion operation (for reflux or weight) vs about 1 in 20 after bypass; new reflux was more common after sleeve.
Conversions 29.9% after SG vs 5.5% after RYGB; better GERD results after RYGB.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare long-term SG and RYGB
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
217
- 实际发现了什么？
More conversions and de novo GERD after SG
- 观察到的效应有多大？
29.9% vs 5.5% conversions
- 研究结果对日常生活意味着什么？
Sleeve has more long-term reflux problems
- 该研究有哪些局限？
Attrition
- 它对 Elawady 的具体说法说明了什么？
Supports reflux and bypass-preference parts
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Mortality differences
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (10)
-
12 years after gastric bypass
Adams TD et al.. N Engl J Med 2017 · PMID 28930514 · DOI 10.1056/NEJMoa1700459队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究Half of the patients with diabetes were still in remission after 12 years; new diabetes was about 90% less frequent than in non-operated people.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Long-term outcomes
- 研究是如何开展的？
Prospective controlled cohort
- 研究了多少人、动物或样本？
1156 adults
- 实际发现了什么？
Remission declines but benefit persists
- 观察到的效应有多大？
Remission 51% at 12 y; incident T2D OR 0.08
- 研究结果对日常生活意味着什么？
Relapse happens, but many stay in remission
- 该研究有哪些局限？
Non-randomized; small diabetic subgroup; many controls later had surgery; mostly women in Utah
- 它对 Elawady 的具体说法说明了什么？
Relapse claim true; 'benefit erodes away' overstated
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Exact causal effect; outcomes for sleeve gastrectomy
-
Italian 10-year diabetes surgery trial
Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0随机对照试验独立交叉核查已核查摘要★ 关键研究More than half of those in remission at 2 years relapsed, but their sugar control stayed good (HbA1c 6.7%) and complications were fewer than with medicines alone.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Durability
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
60
- 实际发现了什么？
Relapse frequent; control better
- 观察到的效应有多大？
RR complications 0.07
- 研究结果对日常生活意味着什么？
Relapse does not mean the benefit is lost
- 该研究有哪些局限？
Tiny
- 它对 Elawady 的具体说法说明了什么？
Partly supports
- 研究结果是否适用于德国和欧洲？
European
- 从该研究中明确不能得出什么结论？
Generalizability
-
Alcohol and drugs after surgery
King WC et al.. Surg Obes Relat Dis 2017 · PMID 28528115 · DOI 10.1016/j.soard.2017.03.021队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估One in five bypass patients reported new alcohol problem symptoms within 5 years.
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
SUD
- 研究是如何开展的？
Cohort
- 研究了多少人、动物或样本？
2003
- 实际发现了什么？
Higher after RYGB
- 观察到的效应有多大？
AHR 2.08
- 研究结果对日常生活意味着什么？
Alcohol risk is real, mainly after bypass
- 该研究有哪些局限？
No non-surgical control; self-reported screening symptoms; 22-34% missing at each follow-up; sleeve not studied
- 它对 Elawady 的具体说法说明了什么？
Supports
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Sleeve-specific risk
-
Swedish study: fractures after gastric bypass
Axelsson KF et al.. J Bone Miner Res 2018 · PMID 30011091 · DOI 10.1002/jbmr.3553队列研究独立交叉核查已核查摘要Fracture risk was about 26-32% higher than in similar people without surgery.
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Fracture
- 研究是如何开展的？
Matched cohort
- 研究了多少人、动物或样本？
~78,000
- 实际发现了什么？
Higher risk
- 观察到的效应有多大？
HR 1.26-1.32
- 研究结果对日常生活意味着什么？
Bone protection is important after bypass
- 该研究有哪些局限？
Short follow-up
- 它对 Elawady 的具体说法说明了什么？
Supports (bypass)
- 研究结果是否适用于德国和欧洲？
European
- 从该研究中明确不能得出什么结论？
Sleeve risk
-
Bowel obstruction after gastric bypass
Elms L et al.. Surg Endosc 2014 · PMID 24380988 · DOI 10.1007/s00464-013-3361-1病例系列 / 病例报告被 Tayebat 档案网站引用已核查摘要About 4 in 100 patients needed another operation for possible bowel obstruction.
该研究是否支持这一具体说法？ 不明确 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Complication causes
- 研究是如何开展的？
Retrospective review
- 研究了多少人、动物或样本？
2395
- 实际发现了什么？
3.9% reoperation
- 观察到的效应有多大？
3.9%
- 研究结果对日常生活意味着什么？
Late complications occur
- 该研究有哪些局限？
Single centre
- 它对 Elawady 的具体说法说明了什么？
General harm, not sleeve-specific
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Comparison with non-surgery
-
Ulcers after gastric bypass
Sverdén E et al.. Ann Surg 2016 · PMID 26106845 · DOI 10.1097/SLA.0000000000001300队列研究被 Tayebat 档案网站引用已核查摘要Diabetes and earlier ulcers increased the risk of ulcers at the new stomach connection.
该研究是否支持这一具体说法？ 不明确 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Risk factors
- 研究是如何开展的？
Registry cohort
- 研究了多少人、动物或样本？
20,294
- 实际发现了什么？
See results
- 观察到的效应有多大？
HR 1.26-2.70
- 研究结果对日常生活意味着什么？
Ulcers are a known complication
- 该研究有哪些局限？
Registry coding
- 它对 Elawady 的具体说法说明了什么？
Indirect
- 研究结果是否适用于德国和欧洲？
European
- 从该研究中明确不能得出什么结论？
Incidence vs non-surgery
-
Trials comparing bypass and sleeve: vitamin and iron deficiency
Kwon et al.. Obes Rev 2022 · PMID 35048495 · DOI 10.1111/obr.13419Meta分析独立交叉核查已核查摘要Anaemia and iron deficiency were similar after bypass and sleeve, but B12 deficiency was about twice as common after bypass.
Bypass carries higher B12-deficiency risk than sleeve.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare deficiencies RYGB vs SG
- 研究是如何开展的？
Meta-analysis of RCTs
- 研究了多少人、动物或样本？
10 RCTs
- 实际发现了什么？
B12 deficiency higher after RYGB
- 观察到的效应有多大？
RR 1.86
- 研究结果对日常生活意味着什么？
Type of operation matters
- 该研究有哪些局限？
Few trials
- 它对 Elawady 的具体说法说明了什么？
Refines the claim
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Very long-term rates
-
French study: broken bones after obesity surgery
Paccou et al.. J Bone Miner Res 2020 · PMID 32187759 · DOI 10.1002/jbmr.4012队列研究独立交叉核查已核查摘要★ 关键研究Serious osteoporotic fractures increased after gastric bypass (about 70% more) but not after sleeve.
Bypass has higher fracture risk than sleeve.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Fracture risk by operation
- 研究是如何开展的？
National cohort
- 研究了多少人、动物或样本？
81,984
- 实际发现了什么？
Bypass HR 1.70; sleeve not increased
- 观察到的效应有多大？
HR 1.22 overall
- 研究结果对日常生活意味着什么？
Bone risk depends on operation
- 该研究有哪些局限？
Administrative data
- 它对 Elawady 的具体说法说明了什么？
Limits the claim for sleeve
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Very long-term risk
-
Trial: bone after bypass vs sleeve
Hofsø et al.. J Clin Endocrinol Metab 2021 · PMID 33150385 · DOI 10.1210/clinem/dgaa808随机对照试验独立交叉核查已核查摘要Hip and spine bone density fell more after bypass than after sleeve.
Bypass carries more bone loss than sleeve.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Bone effects RYGB vs SG
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
92
- 实际发现了什么？
More bone loss after bypass
- 观察到的效应有多大？
Spine -4.2% difference
- 研究结果对日常生活意味着什么？
Bypass is harder on bone
- 该研究有哪些局限？
Small, short
- 它对 Elawady 的具体说法说明了什么？
Refines the claim
- 研究结果是否适用于德国和欧洲？
Directly European
- 从该研究中明确不能得出什么结论？
Fracture risk
-
Meta-analysis: survival after sleeve vs bypass
Sakurai et al.. Surg Obes Relat Dis 2025 · PMID 39732586 · DOI 10.1016/j.soard.2024.11.016Meta分析独立交叉核查已核查摘要Sleeve was associated with about 15% lower death risk than bypass over about 3 years, but needed more revision operations.
SG associated with lower mortality, reoperation and hospitalisation than RYGB, but more revisions.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Mortality SG vs RYGB
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
333,713
- 实际发现了什么？
SG HR 0.85
- 观察到的效应有多大？
HR 0.85
- 研究结果对日常生活意味着什么？
Sleeve is not riskier for survival than bypass
- 该研究有哪些局限？
Observational, short
- 它对 Elawady 的具体说法说明了什么？
Limits bypass-preferred claim
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Long-term difference
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (1)
-
STAMPEDE: surgery vs medicines for diabetes
Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869随机对照试验被 Tayebat 档案网站引用全文，含结构化偏倚风险评估After 5 years, 23-29% of operated patients reached near-normal HbA1c vs 5% with medicines alone.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Diabetes RCT
- 研究是如何开展的？
RCT
- 研究了多少人、动物或样本？
150
- 实际发现了什么？
Surgery better
- 观察到的效应有多大？
29%/23% vs 5%
- 研究结果对日常生活意味着什么？
Surgery helps more, but most did not reach the target and only 15-22% reached it without diabetes medicines
- 该研究有哪些局限？
Small single-centre trial; not blinded; more drop-outs in the medical group; ITT result not significant
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'benefit erodes away'
- 研究结果是否适用于德国和欧洲？
Applicable
- 从该研究中明确不能得出什么结论？
Hard outcomes
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
埃及
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
在我的国家适用什么？
一般科学评估
基本正确 在反流和糖尿病方面的比较对胃旁路术有利，但胃旁路术并不能使大多数患者的糖尿病彻底治愈，而且有其自身的风险，因此它并不是对每个人都合适的选择。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial.. Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229
- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial.. Peterli R et al.. JAMA 2018 · PMID 29340679 · DOI 10.1001/jama.2017.20897
- Gastroesophageal Reflux and Laparoscopic Sleeve Gastrectomy: Results of the First International Consensus Conference.. Assalia et al.. Obes Surg 2020 · PMID 32533520 · DOI 10.1007/s11695-020-04749-0
- Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.. Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6
- Meta-analysis of Long-Term Relapse Rate of Type 2 Diabetes Following Initial Remission After Roux-en-Y Gastric Bypass.. Yu et al.. Obes Surg 2021 · PMID 34505971 · DOI 10.1007/s11695-021-05692-4
- Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study.. McTigue et al.. JAMA Surg 2020 · PMID 32129809 · DOI 10.1001/jamasurg.2020.0087
- Long-Term Outcomes of Laparoscopic Roux-en-Y Gastric Bypass vs Laparoscopic Sleeve Gastrectomy for Obesity: The SM-BOSS Randomized Clinical Trial.. Kraljevic et al.. JAMA Surg 2025 · PMID 39969869 · DOI 10.1001/jamasurg.2024.7052
- Weight and Metabolic Outcomes 12 Years after Gastric Bypass.. Adams TD et al.. N Engl J Med 2017 · PMID 28930514 · DOI 10.1056/NEJMoa1700459
- Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.. Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0
- Alcohol and other substance use after bariatric surgery: prospective evidence from a U.S. multicenter cohort study.. King WC et al.. Surg Obes Relat Dis 2017 · PMID 28528115 · DOI 10.1016/j.soard.2017.03.021
- Fracture Risk After Gastric Bypass Surgery: A Retrospective Cohort Study.. Axelsson KF et al.. J Bone Miner Res 2018 · PMID 30011091 · DOI 10.1002/jbmr.3553
- Causes of small bowel obstruction after Roux-en-Y gastric bypass: a review of 2,395 cases at a single institution.. Elms L et al.. Surg Endosc 2014 · PMID 24380988 · DOI 10.1007/s00464-013-3361-1
- Risk Factors for Marginal Ulcer After Gastric Bypass Surgery for Obesity: A Population-based Cohort Study.. Sverdén E et al.. Ann Surg 2016 · PMID 26106845 · DOI 10.1097/SLA.0000000000001300
- Comparative risk of anemia and related micronutrient deficiencies after Roux-en-Y gastric bypass and sleeve gastrectomy in patients with obesity: An updated meta-analysis of randomized controlled trials.. Kwon et al.. Obes Rev 2022 · PMID 35048495 · DOI 10.1111/obr.13419
- Gastric Bypass But Not Sleeve Gastrectomy Increases Risk of Major Osteoporotic Fracture: French Population-Based Cohort Study.. Paccou et al.. J Bone Miner Res 2020 · PMID 32187759 · DOI 10.1002/jbmr.4012
- Bone Mineral Density and Turnover After Sleeve Gastrectomy and Gastric Bypass: A Randomized Controlled Trial (Oseberg).. Hofsø et al.. J Clin Endocrinol Metab 2021 · PMID 33150385 · DOI 10.1210/clinem/dgaa808
- Comparative survival of sleeve gastrectomy versus Roux-en-Y gastric bypass in adults with obesity: a systematic review and meta-analysis.. Sakurai et al.. Surg Obes Relat Dis 2025 · PMID 39732586 · DOI 10.1016/j.soard.2024.11.016
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.. Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869